Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction

Inflammation Research

Volumn 61, Issue 7, 2012, Pages 725-734

  Swiatkiewicz, Iwona ^a   Kozinski, Marek ^a   Magielski, Przemyslaw ^a   Gierach, Joanna ^a   Fabiszak, Tomasz ^a   Kubica, Aldona ^a   Sukiennik, Adam ^a   Navarese, Eliano Pio ^a   Odrowaz Sypniewska, Grazyna ^a   Kubica, Jacek ^a  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Acute myocardial infarction; C reactive protein; Echocardiography; Inflammation; Left ventricular function

Indexed keywords

BIOLOGICAL MARKER; BRAIN NATRIURETIC PEPTIDE; C REACTIVE PROTEIN; TROPONIN I;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ASSESSMENT; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; IMMUNOASSAY; LEFT VENTRICULAR SYSTOLIC DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; PERCUTANEOUS CORONARY INTERVENTION; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; UPREGULATION;

AGED; ANGIOPLASTY, BALLOON, CORONARY; ANTI-ARRHYTHMIA AGENTS; ANTIHYPERTENSIVE AGENTS; ASPIRIN; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; FEMALE; HEPARIN; HUMANS; MALE; METOPROLOL; MIDDLE AGED; MYOCARDIAL INFARCTION; PERINDOPRIL; PLATELET AGGREGATION INHIBITORS; PROSPECTIVE STUDIES; RISK FACTORS; TICLOPIDINE; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84865139743     PISSN: 10233830     EISSN: 1420908X     Source Type: Journal    
DOI: 10.1007/s00011-012-0466-2     Document Type: Article

References (36)

1. Weir RA, McMurray JJ, Velazquez EJ. Epidemiology of heart failure and left ventricular systolic dysfunction after acute myocardial infarction: prevalence, clinical characteristics, and prognostic importance. Am J Cardiol. 2006;97(10A):13F-25F.
2. Velazquez EJ, Francis GS, Armstrong PW, Aylward PE, Diaz R, O'Connor CM, et al. An international perspective on heart failure and left ventricular systolic dysfunction complicating myocardial infarction: the VALLIANT Registry. Eur Heart J. 2004;25:1911-9. (Pubitemid 39452608)
3. Cleland JG, Torabi A, Khan NK. Epidemiology and management of heart failure and left ventricular systolic dysfunction in the aftermath of a myocardial infarction. Heart. 2005;91(Suppl 2):ii7-13.
4. Kümler T, Gislason GH, Køber L, Torp-Pedersen C. Persistence of the prognostic importance of left ventricular systolic function and heart failure after myocardial infarction: 17-year follow-up of the TRACE register. Eur J Heart Fail. 2010;12:805-11.
5. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53:31-47. (Pubitemid 34020764)
6. Nian M, Lee P, Khaper N, Liu P. Inflammatory cytokines and postmyocardial infarction remodeling. Circ Res. 2004;94:1543-53. (Pubitemid 38856961)
7. Bonvini RF, Hendiri T, Camenzind E. Inflammatory response post-myocardial infarction and reperfusion: a new therapeutic target? Eur Heart J. 2005;7(Suppl I):I27-36. (Pubitemid 43051637)
8. Uehara K, Nomura M, Ozaki Y, Fujinaga H, Ikefuji H, Kimura M, et al. High-sensitivity C-reactive protein and left ventricular remodeling in patients with acute myocardial infarction. Heart Vessels. 2003;18:67-74. (Pubitemid 36701549)
9. Anzai T, Yoshikawa T, Shiraki H, Asakura Y, Akaishi M, Mitamura H, et al. C-reactive protein as a predictor of infarct expansion and cardiac rupture after a first Q-wave acute myocardial infarction. Circulation. 1997;96:778-84. (Pubitemid 27329609)
10. Suleiman M, Khatib R, Agmon Y, Mahamid R, Boulos M, Kapeliovich M, et al. Early inflammation and risk of long-term development of heart failure and mortality in survivors of acute myocardial infarction-predictive role of C-reactive protein. J Am Coll Cardiol. 2006;47:962-8.
11. Scirica BM, Morrow DA, Cannon CP, de Lemos JA, Murphy S, Sabatine MS, et al. Clinical application of C-reactive protein across the spectrum of acute coronary syndromes. Clin Chem. 2007;53:1800-7. (Pubitemid 47509673)
12. Smit JJ, Ottervanger JP, Slingerland RJ, Kolkman JJ, Suryapranata H, Hoorntje JC, et al. Comparison of usefulness of C-reactive protein versus white blood cell count to predict outcome after primary percutaneous coronary intervention for ST elevation myocardial infarction. Am J Cardiol. 2008;101:446-51. (Pubitemid 351199429)
13. Kruk M, Przyłuski J, Kalińczuk Ł, Pregowski J, Deptuch T, Kadziela J, et al. Association of non-specific inflammatory activation with early mortality in patients with ST-elevation acute coronary syndrome treated with primary angioplasty. Circ J. 2008;72:205-11. (Pubitemid 351413357)
14. Schiele F, Meneveau N, Seronde MF, Chopard R, Descotes-Genon V, Dutheil J, et al. C-reactive protein improves risk prediction in patients with acute coronary syndromes. Eur Heart J. 2010;31:290-7.
15. Møller JE, Brendorp B, Ottesen M, Køber L, Egstrup K, Poulsen SH, et al. Congestive heart failure with preserved left ventricular systolic function after acute myocardial infarction: clinical and prognostic implications. Eur J Heart Fail. 2003;5:811-9. (Pubitemid 38198069)
16. Rott D, Behar S, Hod H, Feinberg MS, Boyko V, Mandelzweig L, et al. Improved survival of patients with acute myocardial infarction with significant left ventricular dysfunction undergoing invasive coronary procedures. Am Heart J. 2001;141:267-76. (Pubitemid 32128733)
17. Schiller NB, Shah PM, Crawford M, DeMaria A, Devereux R, Feigenbaum H, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. J Am Soc Echocardiogr. 1989;2:358-67.
18. Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, et al. Recommendations for chamber quantification. Eur J Echocardiogr. 2006;7:79-108. (Pubitemid 43257193)
19. Devereux RB, Alonso DR, Lutas EM, Gottlieb GJ, Campo E, Sachs I, et al. Echocardiographic assessment of left ventricular hypertrophy: comparison to necropsy findings. Am J Cardiol. 1986;57:450-8. (Pubitemid 16119719)
20. Widmer A, Linka AZ, Attenhofer Jost CH, Buergi B, Brunner-La Rocca HP, Salomon F, et al. Mechanical complications after myocardial infarction reliably predicted using C-reactive protein levels and lymphocytopenia. Cardiology. 2003;99:25-31. (Pubitemid 36206632)
21. Anzai T, Yoshikawa T, Kaneko H, Maekawa Y, Iwanaga S, Asakura Y, et al. Association between serum C-reactive protein elevation and left ventricular thrombus formation after first anterior myocardial infarction. Chest. 2004;125:384-9. (Pubitemid 38223612)
22. Zebrack JS, Anderson JL. Should C-reactive protein be measured routinely during acute myocardial infarction? Am J Med. 2003;115:735-7. (Pubitemid 38032669)
23. Aggelopoulos P, Chrysohoou C, Pitsavos C, Papadimitriou L, Liontou C, Panagiotakos D, et al. Comparative value of simple inflammatory markers in the prediction of left ventricular systolic dysfunction in postacute coronary syndrome patients. Mediators Inflamm. 2009;2009:826297.
24. Arruda-Olson AM, Enriquez-Sarano M, Bursi F, Weston SA, Jaffe AS, Killian JM, et al. Left ventricular function and C-reactive protein levels in acute myocardial infarction. Am J Cardiol. 2010;105:917-21.
25. Brunetti ND, Troccoli R, Correale M, Pellegrino PL, Di Biase M. C-reactive protein in patients with acute coronary syndrome: correlation with diagnosis, myocardial damage, ejection fraction and angiographic findings. Int J Cardiol. 2006;109:248-56.
26. James SK, Oldgren J, Lindbäck J, Johnston N, Siegbahn A, Wallentin L. An acute inflammatory reaction induced by myocardial damage is superimposed on a chronic inflammation in unstable coronary artery disease. Am Heart J. 2005;149:619-26.
27. Ohlmann P, Jaquemin L, Morel O, El Behlgiti R, Faure A, Michotey MO, et al. Prognostic value of C-reactive protein and cardiac troponin I in primary percutaneous interventions for STelevation myocardial infarction. Am Heart J. 2006;152:1161-7. (Pubitemid 44854795)
28. Ørn S, Manhenke C, Ueland T, Damås JK, Mollnes TE, Edvardsen T, et al. C-reactive protein, infarct size, microvascular obstruction, and left-ventricular remodelling following acute myocardial infarction. Eur Heart J. 2009;30:1180-6.
29. Kitsis R, Jialal I. Limiting myocardial damage during acute myocardial infarction by inhibiting C-reactive protein. N Engl J Med. 2006;355:513-5. (Pubitemid 44162281)
30. Pepys MB, Hirschfield GM, Tennent GA, Gallimore JR, Kahan MC, Bellotti V, et al. Targeting C-reactive protein for the treatment of cardiovascular disease. Nature. 2006;440:1217-21.
31. Lagrand WK, Niessen HW, Wolbink GJ, Jaspars LH, Visser CA, Verheugt FW, et al. C-reactive protein colocalizes with complement in human hearts during acute myocardial infarction. Circulation. 1997;95:97-103. (Pubitemid 27029949)
32. Griselli M, Herbert J, Hutchinson WL, Taylor KM, Sohail M, Krausz T, et al. C-reactive protein and complement are important mediators of tissue damage in acute myocardial infarction. J Exp Med. 1999;190:1733-40.
33. Barrett TD, Hennan JK, Marks RM, Lucchesi BR. C-reactiveprotein- associated increase in myocardial infarct size after ischemia/reperfusion. J Pharmacol Exp Ther. 2002;303:1007-13. (Pubitemid 35424383)
34. Takahashi T, Anzai T, Kaneko H, Mano Y, Anzai A, Nagai T, et al. Increased C-reactive protein expression exacerbates left ventricular dysfunction and remodeling after myocardial infarction. Am J Physiol Heart Circ Physiol. 2010;299:H1795-804.
35. Verma S, Wang CH, Li SH, Dumont AS, Fedak PW, Badiwala MV, et al. A self-fulfilling prophecy: C-reactive protein attenuates nitric oxide production and inhibits angiogenesis. Circulation. 2002;106:913-9. (Pubitemid 34925323)
36. Verma S, Kuliszewski MA, Li SH, Szmitko PE, Zucco L, Wang CH, et al. C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function: further evidence of a mechanistic link between C-reactive protein and cardiovascular disease. Circulation. 2004;109:2058-67. (Pubitemid 38620212)